Compare SXTP & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SXTP | PPCB |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.6M |
| IPO Year | 2023 | 2011 |
| Metric | SXTP | PPCB |
|---|---|---|
| Price | $1.06 | $2.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.10 | N/A |
| AVG Volume (30 Days) | 78.3K | ★ 107.6K |
| Earning Date | 05-15-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,005,471.00 | N/A |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $51.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.49 | N/A |
| 52 Week Low | $0.34 | $0.06 |
| 52 Week High | $8.62 | $6.79 |
| Indicator | SXTP | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 35.82 | 75.56 |
| Support Level | $1.05 | $1.42 |
| Resistance Level | $1.12 | $2.41 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 24.00 | 36.20 |
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.